Biosimilars: Scale up from R&D to Commercial Stage

  • Madhusudan Dabhole Richcore Life Sciences Ltd
Keywords: Biosimilars, Research, Recombinant Proteins, Market

Abstract

The scale up of recombinant proteins involves a multi- dynamic strategic approach to achieve maximum output consistently. Various parameters during the fermentation will limit the synthesis of desired protein, which otherwise can be produced with ease in case of classical fermentation. In order to synthesis the protein, it is very important to understand the process at laboratory scale – both from scale up point of view and productivity improvement at large scale. Some of this parameters and scale up parameters are discussed below in this review.

Author Biography

Madhusudan Dabhole, Richcore Life Sciences Ltd

Group Manager - BioProcess,
Richcore Life Sciences Ltd,
Bangalore, Karnataka, India.

References

1. Sheldon E. Broedel, Jr. et al, The Selection of Optimum Media Formulations for Improved Expression of Recombinant Proteins in E. coli, Technical Bulletin, Athena Environmental Sciences, Inc., Baltimore, MD. Vol 2, 2001. 2. Nagesh Kumar Tripathi, Production, Purification and Characterization of RecombinantViral Proteins. Ph.D Thesis.Dep
Published
2015-01-01
How to Cite
[1]
Dabhole, M. 2015. Biosimilars: Scale up from R&D to Commercial Stage. PharmaTutor. 3, 1 (Jan. 2015), 10-13.
Section
Articles